Charles River Laboratories

4Q Revenues: $329.5 million (+14%)

4Q Earnings: $27.7 million (+43%)

FY Revenues: $1.3 billion (+11%)

FY Earnings: $128.2 million (+23%)

Comments: Research Models and Services (RMS) revenues were $117.7 million in the quarter, down 4% impacted by exchange rates.  Discovery and Safety Assessment (DSA) was $149.6 million, up 35% driven primarily by the Early Discovery acquisitions, which contributed 24%. Manufacturing revenue was $62.3 million in the quarter, up 11% driven by double-digit growth in the Endotoxin and Microbial Detection business.